Thursday, October 12, 2017

EMA advisory group backs Orphan Drug tag for Soleno's DCCR for Prader-Willi syndrome; shares up 2%

  1. EMA advisory group backs Orphan Drug tag for Soleno's DCCR for Prader-Willi syndrome; shares up 2%  Seeking Alpha
  2. Soleno Therapeutics (SLNO) Announces New US Patent for DCCR Covering Treatment of Hyperphagia in PWS  StreetInsider.com
  3. Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome  GlobeNewswireFull coverage

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Headlines